Evaluation of the Effect of Nirsevimab on Hospitalizations Due to RSV Infection in Infants Under One Year of Age.

NCT06856967 · clinicaltrials.gov ↗

RECRUITING

Status

138

Enrollment

OTHER

Sponsor class

Conditions

Respiratory Synctial Virus Infections

Interventions

DRUG: Nirsevimab

Sponsor

Meyer Children's Hospital IRCCS